Michael Newman
Company: Indaptus Therapeutics, Inc.
Job title: Founder and Chief Scientific Officer
Seminars:
Chair’s Closing Remarks 3:30 pm
day: Conference Day Two
Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy 12:15 pm
Investigating how we can better control the duration and intensity of cytokine signalling to improve therapeutic outcomes Exploring the use of intact, killed, non-pathogenic (Decoy) bacteria as a novel approach to induce pulsed cytokine release and anti-tumor activity in pre-clinical models Presenting data from a clinical oncology trial demonstrating pulsed and exceptionally broad cytokine induction,…Read more
day: Conference Day One
Chair’s Opening Remarks 8:25 am
day: Conference Day Two